Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer.
Arasanz H, Bocanegra AI, Morilla I, Fernández-Irigoyen J, Martínez-Aguillo M, Teijeira L, Garnica M, Blanco E, Chocarro L, Ausin K, Zuazo M, Fernández-Hinojal G, Echaide M, Fernández-Rubio L, Piñeiro-Hermida S, Ramos P, Mezquita L, Escors D, Vera R, Kochan G. Arasanz H, et al. Among authors: teijeira l. Cancers (Basel). 2022 Aug 9;14(16):3846. doi: 10.3390/cancers14163846. Cancers (Basel). 2022. PMID: 36010840 Free PMC article.
PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer.
Bocanegra A, Fernandez-Hinojal G, Zuazo-Ibarra M, Arasanz H, Garcia-Granda MJ, Hernandez C, Ibañez M, Hernandez-Marin B, Martinez-Aguillo M, Lecumberri MJ, Fernandez de Lascoiti A, Teijeira L, Morilla I, Vera R, Escors D, Kochan G. Bocanegra A, et al. Among authors: teijeira l. Int J Mol Sci. 2019 Apr 2;20(7):1631. doi: 10.3390/ijms20071631. Int J Mol Sci. 2019. PMID: 30986912 Free PMC article.
Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy.
Zuazo M, Arasanz H, Fernández-Hinojal G, García-Granda MJ, Gato M, Bocanegra A, Martínez M, Hernández B, Teijeira L, Morilla I, Lecumberri MJ, Fernández de Lascoiti A, Vera R, Kochan G, Escors D. Zuazo M, et al. Among authors: teijeira l. EMBO Mol Med. 2019 Jul;11(7):e10293. doi: 10.15252/emmm.201910293. Epub 2019 Jun 6. EMBO Mol Med. 2019. PMID: 31273938 Free PMC article.
Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics.
Arasanz H, Zuazo M, Bocanegra A, Gato M, Martínez-Aguillo M, Morilla I, Fernández G, Hernández B, López P, Alberdi N, Hernández C, Chocarro L, Teijeira L, Vera R, Kochan G, Escors D. Arasanz H, et al. Among authors: teijeira l. Cancers (Basel). 2020 Feb 4;12(2):344. doi: 10.3390/cancers12020344. Cancers (Basel). 2020. PMID: 32033028 Free PMC article.
Hyperprogressive Disease: Main Features and Key Controversies.
Arasanz H, Zuazo M, Bocanegra A, Chocarro L, Blanco E, Martínez M, Morilla I, Fernández G, Teijeira L, Morente P, Echaide M, Castro N, Fernández L, Garnica M, Ramos P, Escors D, Kochan G, Vera R. Arasanz H, et al. Among authors: teijeira l. Int J Mol Sci. 2021 Apr 3;22(7):3736. doi: 10.3390/ijms22073736. Int J Mol Sci. 2021. PMID: 33916696 Free PMC article. Review.
CAR-T Cells for the Treatment of Lung Cancer.
Chocarro L, Arasanz H, Fernández-Rubio L, Blanco E, Echaide M, Bocanegra A, Teijeira L, Garnica M, Morilla I, Martínez-Aguillo M, Piñeiro-Hermida S, Ramos P, Lasarte JJ, Vera R, Kochan G, Escors D. Chocarro L, et al. Among authors: teijeira l. Life (Basel). 2022 Apr 8;12(4):561. doi: 10.3390/life12040561. Life (Basel). 2022. PMID: 35455052 Free PMC article. Review.
Quality of life of early-stage breast-cancer patients diagnosed with COVID-19 in the first three waves of the epidemic treated in the Spanish region of Navarre.
Arraras JI, Illarramendi JJ, Manterola A, Cruz S, Zarandona U, Ibañez B, Salgado E, Visus I, Barrado M, Teijeira L, Martinez E, Vera R. Arraras JI, et al. Among authors: teijeira l. Psychooncology. 2023 May;32(5):730-740. doi: 10.1002/pon.6118. Epub 2023 Mar 17. Psychooncology. 2023. PMID: 36882856
Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events.
Les I, Martínez M, Pérez-Francisco I, Cabero M, Teijeira L, Arrazubi V, Torrego N, Campillo-Calatayud A, Elejalde I, Kochan G, Escors D. Les I, et al. Among authors: teijeira l. Cancers (Basel). 2023 Mar 6;15(5):1629. doi: 10.3390/cancers15051629. Cancers (Basel). 2023. PMID: 36900420 Free PMC article. Review.
Baseline Circulating Blood Cell Counts and Ratios and Changes Therein for Predicting Immune-Related Adverse Events during Immune Checkpoint Inhibitor Therapy: A Multicenter, Prospective, Observational, Pan-Cancer Cohort Study with a Gender Perspective.
Teijeira L, Martínez M, Moreno A, de Elejoste I, Ibáñez-Beroiz B, Arrazubi V, Díaz de Corcuera I, Elejalde I, Campillo-Calatayud A, Les I. Teijeira L, et al. Cancers (Basel). 2023 Dec 28;16(1):151. doi: 10.3390/cancers16010151. Cancers (Basel). 2023. PMID: 38201577 Free PMC article.
15 results